News

Roche: RoActemra beats Humira
Enlarge image

BusinessSwitzerland

Roche: RoActemra beats Humira

08.06.2012 - Roche's rheumatoid arthritis treatment RoActemra reduces symptoms more effectively than Abbott Laboratories' Humira when given as a single treatment.

Basel – As the Swiss company reported, a Phase IV trial showed that after 24 weeks of treatment 65% of patients who received RoActemra (tocilizumab) experienced a 20% reduction in swollen and tender joints compared with 49% of those on Humira (adalimumab). „As there are a number of therapies approved for patients with rheumatoid arthritis, it is important for them and their healthcare provider to have the information they need to choose the best individual treatment option,“ said Hal Barron, Chief Medical Officer and Head, Global Product Development. While Roche strongly advocates for its RoActemra, Analysts seem to be less convinced: „Despite these strong efficacy results, it is difficult to assess whether these trial results can be successfully exploited to bring about a change in physicians' prescription habits,“ said Vontobel analyst Andrew Weiss.

„Among a treatment environment of nine different medicines, it is very difficult to make an individual treatment decision for the physician“, acknowledged Karsten Jung, Head of GPS Immunology at Roche, adding that the study aimed at giving comparative data to doctors to help them to decidea in favor of RoActemra when prescribing a treatment.

FDA and EMA have approved RoActemra for use in patients who are either intolerant to or have failed to respond to other medicines to treat inflammation. Roche earned CHF184m in the first quarter 2012 (+46%). Analysts expect peak sales of up to US$2b for the drug. Rheumatoid arthritis and related diseases are one of the most lucrative areas for pharma companies, generating more than US$20b in annual sales. Humira sales are expected to reach US$8.7bn in 2012, according to an EvaluatePharma report.

http://www.european-biotechnology-news.com/news/news/2012-02/roche-roactemra-beats-humira.html

FinancingBelgium

20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.

Stock marketsFranceEU

19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.

ResearchUK

18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.

M&AUKSwitzerland

13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.

R&DAustriaFrance

12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.

M&AFranceEU

07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.

Prenatal DiagnosticsEUUK

06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.

GenericsSpainGermanyEU

04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.

Drug discoveryUKSwitzerland

30.06.2016 UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.

Nuclear medicineNorwayFrance

28.06.2016 Nordic Nanovector has teamed up with Areva Med to develop a treatment for leukaemia. The compound in question is a lead-212 conjugated anti-CD37 antibody.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MOLOGEN (D)1.50 EUR12.78%
  • BIOCARTIS GROUP NV (B)7.57 EUR7.53%
  • SWEDISH ORPHAN BIOVITRUM (S)13.11 USD6.59%

FLOP

  • NICOX (F)11.57 EUR-8.61%
  • KAROLINSKA (S)7.55 SEK-4.43%
  • AB SCIENCE (F)14.20 EUR-4.05%

TOP

  • PROTHENA PLC (IE)53.17 USD31.1%
  • THERAMETRICS (CH)0.05 CHF25.0%
  • FLAMEL TECHNOLOGIES (F)12.49 USD24.9%

FLOP

  • MOLOGEN (D)1.50 EUR-40.2%
  • ALLERGY THERAPEUTICS (UK)19.50 GBP-21.2%
  • SAREUM HOLDINGS (UK)0.64 GBP-21.0%

TOP

  • KARO BIO (S)28.70 SEK1693.8%
  • NICOX (F)11.57 EUR515.4%
  • SAREUM HOLDINGS (UK)0.64 GBP156.0%

FLOP

  • BB BIOTECH (D)45.22 EUR-84.8%
  • NEUROVIVE PHARMACEUTICAL AB (S)4.64 SEK-79.6%
  • EVOCUTIS (UK)0.04 GBP-76.5%

No liability assumed, Date: 22.07.2016